美多巴联合普拉克索治疗帕金森病的有效性及安全性

The Efficacy and Safety of Madopar Combined with Pramipexole in the Treatment of Parkinson’s Disease

目的分析美多巴联合普拉克索治疗帕金森病的临床疗效。方法选取2016年5月~2018年5月在我院治疗的80例帕金森病患者为研究对象,采用随机数字表分为对照组和观察组,各40例。对照组采用美多巴治疗,观察组在对照组基础上联合普拉克索治疗,比较两组临床治疗总有效率、不同时间段(治疗1、2、4周)汉密顿抑郁量表(HAMD)评分、Hoehn-Yahr分期改善情况、生活质量评分及临床不良反应(血压下降、胃肠道反应、精神不振、异动症)发生情况。结果观察组临床治疗总有效率(95.00%)高于对照组(82.50%)(P<0.05);观察组治疗1、2、4周时HAMD评分均低于对照组(P<0.05);治疗后观察组HoehnYahr分期Ⅰ、Ⅱ期例数多于对照组,高于Ⅲ、Ⅳ、Ⅴ分期例数少于对照组(P<0.05);治疗后观察组生活质量评分均高于对照组(P<0.05);观察组临床不良反应发生率(2.50%)低于对照组(15.00%)(P<0.05)。结论美多巴联合普拉克索治疗帕金森病有效率高,有助于缓解患者不良情绪,改善临床分期,提高患者生活质量,且不良反应少,应用安全性高,值得临床应用。

Objective To analyze the clinical efficacy of Madopar combined with Pramipexole in the treatment of Parkinson’s disease. Methods 80 patients with Parkinson’s disease who were treated in our hospital from May 2016 to May 2018 were selected as the research object.They were divided into a control group and an observation group with a random number table, 40 cases each.The control group was treated with Madopar, and the observation group was treated with Pramipexole on the basis of the control group.To compare the total clinical effectiveness of the two groups, the Hamilton Depression Scale(HAMD) score, Hoehn-Yahr staging improvement, quality of life score, and clinical adverse reactions(blood pressure drop,gastrointestinal reactions, mental depression, dyskinesias).Results The total effective rate of clinical treatment in the observation group(95.00%) was higher than that in the control group(82.50%)(P<0.05);The HAMD scores of the observation group were lower than those of the control group at 1, 2,and 4 weeks of treatment(P<0.05);after treatment, the number of cases in the Hoehn-Yahr stage Ⅰ and Ⅱ of the observation group was higher than that of the control group, and higher than that of the Ⅲ, Ⅳ, and Ⅴ the number of cases was less than the control group(P<0.05);the quality of life scores of the observation group after treatment were higher than the control group(P<0.05);the incidence of clinical adverse reactions(2.50%) in the observation group was lower than that in the control group(15.00%)(P<0.05).Conclusion Madopar combined with Pramipexole has a high efficiency in the treatment of Parkinson’s disease, which can help alleviate the patients’ bad mood, improve the clinical stage, improve the patient’s quality of life, and has fewer adverse reactions.